SCHEMBL738469

SCHEMBL738469

CC(C)(C)OC(=O)N1CC2CC(=O)CC(C1)N2C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.44
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
USP30 Q70CQ3 1/20 0.40
RORC P51449 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GPR119 Q8TDV5 1/20 0.39
FPR2 P25090 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
HSD11B1 P28845 2/20 0.38
NAMPT P43490 1/20 0.38
HPGD P15428 1/20 0.37
PREP P48147 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL738468 0.90 CHRM2 (0.50) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL737422 0.84 NR1H2 (0.46) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL5243300 0.83 USP2 (0.47) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL24582817 0.81 NR1H2 (0.44) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL22276814 0.81 CHRM2 (0.47) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL20210116 0.81 CHRM2 (0.48) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL29655394 0.80 NR1H2 (0.49) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL4684359 0.80 NR1H2 (0.49) NR1H2CHRM2CHRM1CHRM3DDB1
SCHEMBL22270526 0.78 NR1H2 (0.58) NR1H2DDB1CRBNUSP30RORC
SCHEMBL13727442 0.78 NR1H2 (0.58) NR1H2DDB1CRBNUSP30RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138340-B2 Bicyclononene derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-03-20 US disclosed
EP-1786814-B1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2010-03-31 EP disclosed
US-20090306123-A1 Bicyclononene derivaties ACTELION PHARMACEUTICALS LTD. (CH) 2009-12-10 US disclosed
EP-1786814-A1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2007-05-23 EP disclosed
WO-2006021402-A1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD. (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306123-A1 Bicyclononene derivaties REN, ACE, CYP51A1 NR1H2 1159/4885CHRM2 2876/4885CHRM1 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.